Nurix Therapeutics (NRIX) Stock Price, News & Analysis

Company Overview

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.

Key Stats

• Today's Range: $9.64 to $10.33
• 50-Day Range: $9.53 to $13.18
• 52-Week Range: $8.18 to $29.56
• Volume: 617,554 shs
• Average Volume: 724,761 shs
• Market Capitalization: $775.20 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $28.87
• Consensus Rating: Moderate Buy

Nurix Therapeutics Stock Analysis - MarketRank™

Nurix Therapeutics scored higher than 53% of companies evaluated by MarketBeat, and ranked 505th out of 937 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Nurix Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.81, and is based on 13 buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Nurix Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Nurix Therapeutics are expected to decrease in the coming year, from ($2.99) to ($3.01) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Nurix Therapeutics is -3.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Nurix Therapeutics is -3.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Nurix Therapeutics has a P/B Ratio of 1.36. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

18.41% of the float of Nurix Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Nurix Therapeutics has a short interest ratio ("days to cover") of 15.4, which indicates bearish sentiment.

Change versus previous month

Short interest in Nurix Therapeutics has recently decreased by 6.59%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Nurix Therapeutics does not currently pay a dividend.

Dividend Growth

Nurix Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

18.41% of the float of Nurix Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Nurix Therapeutics has a short interest ratio ("days to cover") of 15.4, which indicates bearish sentiment.

Change versus previous month

Short interest in Nurix Therapeutics has recently decreased by 6.59%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 1.14

News Sentiment

Nurix Therapeutics has a news sentiment score of 1.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Nurix Therapeutics this week, compared to 6 articles on an average week.

Search Interest

Only 3 people have searched for NRIX on MarketBeat in the last 30 days. This is a decrease of -77% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Nurix Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $163,014.00 in company stock.

Percentage Held by Insiders

Only 7.40% of the stock of Nurix Therapeutics is held by insiders.

NRIX Stock Analysis - Frequently Asked Questions

How have NRIX shares performed this year?

Nurix Therapeutics' stock was trading at $18.84 on January 1st, 2025. Since then, NRIX shares have decreased by 46.2% and is now trading at $10.14.

How were Nurix Therapeutics' earnings last quarter?

Nurix Therapeutics, Inc. (NASDAQ:NRIX) issued its quarterly earnings data on Wednesday, July, 9th. The company reported ($0.52) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.79) by $0.27. The firm had revenue of $44,056 billion for the quarter, compared to analyst estimates of $16.26 million. Nurix Therapeutics had a negative net margin of 234.57% and a negative trailing twelve-month return on equity of 45.26%.

When did Nurix Therapeutics IPO?

Nurix Therapeutics (NRIX) raised $150 million in an initial public offering (IPO) on Friday, July 24th 2020. The company issued 8,800,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Piper Sandler and Stifel acted as the underwriters for the IPO and Needham & Company was co-manager.

Who are Nurix Therapeutics' major shareholders?

Nurix Therapeutics' top institutional shareholders include Commodore Capital LP (5.17%), Redmile Group LLC (4.88%), Vestal Point Capital LP (2.62%) and Geode Capital Management LLC (2.46%). Insiders that own company stock include Gwenn Hansen, Houte Hans Van, Christine Ring and Stefani Wolff.
View institutional ownership trends.

How do I buy shares of Nurix Therapeutics?

Shares of NRIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Nurix Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Nurix Therapeutics investors own include Tesla (TSLA), Netflix (NFLX), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Meta Platforms (META), Advanced Micro Devices (AMD) and Visa (V).

Company Calendar

• Last Earnings: 7/09/2025
• Today: 8/24/2025
• Next Earnings (Estimated): 10/10/2025
• Fiscal Year End: 11/30/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:NRIX
• CIK: 1549595
• Web: www.nurixtx.com
• Phone: 415-660-5320
• Fax: N/A
• Employees: 300
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Nurix Therapeutics: $28.87
• High Price Target: $41.00
• Low Price Target: $16.00
• Potential Upside/Downside: +184.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.81
• Research Coverage: 16 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.61)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$193.57 million
• Net Margins: -234.57%
• Pretax Margin: -233.61%
• Return on Equity: -45.26%
• Return on Assets: -34.71%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.82
• Quick Ratio: 6.82

Sales & Book Value

• Annual Sales: $54.55 million
• Price / Sales: 14.21
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.44 per share
• Price / Book: 1.36

Miscellaneous

• Outstanding Shares: 76,450,000
• Free Float: 70,792,000
• Market Cap: $775.20 million
• Optionable: Optionable
• Beta: 2.14